Comparison · NCT06154226-e3eeb8f2
Famotidine Group vs Pantoprazole Group: Number of Participants With Any-stage Postoperative Acute Kidney Injury (AKI)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Famotidine Group vs Pantoprazole Group: Number of Participants With Any-stage Postoperative Acute Kidney Injury (AKI). Trial comparisons, record NCT06154226-e3eeb8f2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06154226-e3eeb8f2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.531 | 0.394 | 0.663 | wilson | |
| Risk in group 2 | 0.388 | 0.264 | 0.528 | wilson | |
| Risk difference, group 1 minus group 2 | 0.143 | -0.0527 | 0.324 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.37 | 0.882 | 2.12 | log | |
| Odds ratio, group 1 over group 2 | 1.78 | 0.8 | 3.98 | log | |
| Number needed to treat, for one more participant with the outcome on Famotidine Group than on Pantoprazole Group | 7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Famotidine Group | Famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.~Famotidine: Subjects will receive famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days. | 26 | 49 | OG000 |
| Group 2 | Pantoprazole Group | Pantoprazole (40 mg iv every 12 hours/q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on postoperative (POD) 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.~Pantoprazole: Subjects will receive pantoprazole (40 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on post operative day 1 (POD 1) for a total of 4 doses over 2 days. | 19 | 49 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Any-stage Postoperative Acute Kidney Injury (AKI)
- Description
Acute kidney injury (AKI) will be defined using the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria: serum creatinine (SCr) increase greater than 50% from baseline or ≥ 0.3 mg/dL increase within 48 hours after surgery.
- Time frame
- from baseline to postoperative day 7 (or hospital discharge if earlier)
- Population
All 100 participants completed the study; however, upon further verification before analysis, 2 participants who completed (1 per arm) were deemed to not meet the inclusion criteria; therefore, these 2 participants (1 per arm) were excluded from the analysis. An intent-to-treat analysis is reported.
Source ClinicalTrials.gov
Trial
- Title
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor
- NCT number
- NCT06154226
- Phases
- PHASE2
- Conditions
- Acute Kidney Injury
- Interventions
- Pantoprazole, Famotidine
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Results first posted
- 2026-03-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06154226?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06154226-e3eeb8f2